Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | BAX | Q07812 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13289 | 0.91 | LTA4H (0.50) | CA4LTA4HTSHRLMNAALOX12 | |
| SCHEMBL11871889 | 0.88 | LTA4H (0.47) | CA4LTA4HTSHRLMNAALOX12 | |
| SCHEMBL11679017 | 0.88 | LTA4H (0.47) | CA4LTA4HTSHRLMNAALOX12 | |
| SCHEMBL19327377 | 0.88 | LTA4H (0.47) | CA4LTA4HTSHRLMNAALOX12 | |
| SCHEMBL8113527 | 0.88 | LTA4H (0.47) | CA4LTA4HTSHRLMNAALOX12 | |
| SCHEMBL8662152 | 0.88 | LTA4H (0.47) | CA4LTA4HTSHRLMNAALOX12 | |
| SCHEMBL3009883 | 0.88 | LTA4H (0.47) | CA4LTA4HTSHRLMNAALOX12 | |
| Hydrochloric Acid SCHEMBL3848860 | 0.88 | LTA4H (0.47) | CA4LTA4HTSHRLMNAALOX12 | |
| SCHEMBL11681119 | 0.88 | LTA4H (0.47) | CA4LTA4HTSHRLMNAALOX12 | |
| SCHEMBL16415989 | 0.88 | LTA4H (0.47) | CA4LTA4HTSHRLMNAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114181330-A | Preparation method of sugammadex intermediate | 鲁南制药集团股份有限公司 | 2022-03-15 | — | — | CN | claimed |
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20250236623-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2025-07-24 | — | — | US | disclosed |
| WO-2024182569-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-09-06 | — | — | WO | disclosed |
| EP-4122932-A1 | PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3505173-B1 | PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-112723982-B | Preparation method of benzyl iodide and derivatives thereof | 湖南科技大学 | 2022-03-18 | — | — | CN | disclosed |
| CN-114181330-A | Preparation method of sugammadex intermediate | 鲁南制药集团股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-114181330-A | Preparation method of sugammadex intermediate | 鲁南制药集团股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| EP-3683222-B1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-10-06 | — | — | EP | disclosed |
| EP-0080286-A1 | Antibacterial compounds containing beta-lactams, processes for their preparation and their use | BEECHAM GROUP PLC (GB) | 1983-06-01 | — | — | EP | disclosed |
| US-4255432-A | ANTIHYPERTENSIVE AGENTS, ANTIHISTAMINES, BRONCHODILATOR AGENTS, ANTIVASOSPASTIC AGENTS | SYNTEX (U.S.A.) INC. (US) | 1981-03-10 | — | — | US | disclosed |
| US-4071680-A | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1978-01-31 | — | — | US | disclosed |
| US-3984446-A | Process for preparation of terpene flavorants and novel intermediates therefor | GIVAUDAN CORPORATION (US) | 1976-10-05 | — | — | US | disclosed |
| US-3974226-A | Process for preparation of terpene flavorants and novel intermediates therefor | GIVAUDAN CORPORATION (US) | 1976-08-10 | — | — | US | disclosed |
| US-3965198-A | 4-Methylene-5-hexen-1-ol | GIVAUDAN CORPORATION (US) | 1976-06-22 | — | — | US | disclosed |
| US-3962283-A | TERPENE FLAVORANT INTERMEDIATES | GIVAUDAN CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
| US-3950430-A | Process for preparation of terpene flavorants and novel intermediates therefor | GIVAUDAN CORPORATION (US) | 1976-04-13 | — | — | US | disclosed |
| US-3939206-A | Process for preparation of terpene flavorants and novel intermediates therefor | GIVAUDAN CORPORATION (US) | 1976-02-17 | — | — | US | disclosed |
| US-3935275-A | Process for preparation of terpene flavorants and novel intermediates therefor | GIVAUDAN CORPORATION (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236623-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | SYNJ1, SARS1, SYNJ2 | CA4 1752/4885LTA4H 3090/4885TSHR 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.